From Barchart: 2025-05-06 02:12:00

Vertex Pharmaceuticals reported a Q1 revenue miss, with Trikafta sales up 2% to $2.53 billion, falling short of analysts’ $2.58 billion estimate. Shares dropped 2.5% after hours. Despite this, Vertex raised the lower end of its 2024 revenue forecast, citing early traction from new drugs and gene therapy rollouts.

BMO Capital’s Evan Seigerman highlighted scrutiny on Journavx’s rollout execution due to the revenue gap. Investors are closely watching Vertex’s ability to convert prescriptions into revenue, especially with newer launches like Alyftrek. Monitoring revenue segmentation and R&D investments is crucial for long-term growth sustainability.

Vertex’s expansion beyond cystic fibrosis relies on successful launches like Journavx. The company’s ability to drive revenue from new products will be key in supporting its optimistic long-term outlook.



Read more at Barchart:: Vertex Misses Q1 Estimates on Trikafta Sales, But …